-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Nektar Therapeutics, Lowers Price Target to $149

Benzinga·11/16/2026 20:16:54
Listen to the news
Canaccord Genuity analyst Edward Nash maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and lowers the price target from $153 to $149.